Similar articles

• [Differentiation induction of leukemic cells in acute myeloid leukemia].

  Suzuki K, Yokoyama S, Asano Y, Tomoyasu S, Tsuruoka N, Hozumi M. Suzuki K, et al. Rinsho Ketsueki. 1984 Feb;25(2):241-5. Rinsho Ketsueki. 1984. PMID: 6590884 Japanese. No abstract available.
• [Preliminary results of the treatment of non-lymphoblastic leukemia and bone marrow dysplasia with small doses of cytosine arabinoside].

  Brodzki LM. Brodzki LM. Acta Haematol Pol. 1985 Jan-Jun;16(1-2):85-9. Acta Haematol Pol. 1985. PMID: 3914171 Review. Polish. No abstract available.
• [Abnormalities of the erythropoiesis at the beginning of remission in acute promyelocytic leukemia treated with arabinoside-cytosine].

  Dubois-Ferrière H, Aguercif M, Hazeghi P, Rudhardt M. Dubois-Ferrière H, et al. Schweiz Med Wochenschr. 1970 Feb 14;100(7):321-3. Schweiz Med Wochenschr. 1970. PMID: 5263342 French. No abstract available.
• [Low dose Ara-C for remission induction in aged patients with atypical nonlymphocytic leukemia and refractory anemia with excess blasts].

  Sawada H, Yamagishi M, Mochizuki T, Ishikura H, Izumi Y, Park YH, Wano M, Usui T, Uchino H, et al. Sawada H, et al. Rinsho Ketsueki. 1983 Nov;24(11):1464-72. Rinsho Ketsueki. 1983. PMID: 6584648 Japanese. No abstract available.
• To overcome pharmacologic and cytokinetic resistance to cytarabine in the treatment of acute myelogenous leukemia by using recombinant interleukin-3?

  Brach MA, Henschler R, Mertelsmann R, Herrmann F. Brach MA, et al. Semin Hematol. 1991 Jul;28(3 Suppl 4):39-43. Semin Hematol. 1991. PMID: 1780751 Review. No abstract available.